Obesity: A Focus on Pharmacotherapy

被引:0
|
作者
Wong, Elaine [1 ]
Kaur, Navneet [2 ]
Ma, Nicholas [2 ]
Patel, Kinjal [2 ]
Ringel, Moshe [2 ]
机构
[1] Long Isl Univ, Pharm Practice, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY 11201 USA
[2] Long Isl Univ, Arnold & Marie Schwartz Coll Pharm & Hlth Sci, Brooklyn, NY USA
来源
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2013年 / 9卷 / 06期
关键词
diethylpropion; lorcaserin; obesity; orlistat; phentermine; phentermine/topiramate; WEIGHT-LOSS; CONTROLLED-RELEASE; OVERWEIGHT ADULTS; LORCASERIN; TRIAL;
D O I
10.1016/j.nurpra.2013.03.015
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Obesity is a condition associated with a vast number of health complications. Clinicians should initially counsel obese patients (defined as a body mass index >= 30 kg/m(2)) on lifestyle modifications to achieve and sustain weight loss. The addition of pharmacologic therapy can be considered in patients who do not have satisfactory outcomes with this approach. Currently, several pharmacologic therapies have received Food and Drug Administration approval. This article reviews pharmacologic data and relevant clinical literature with which a nurse practitioner should be familiar when prescribing and evaluating the safety and efficacy of weight loss medications in obese patients.
引用
收藏
页码:387 / 395
页数:9
相关论文
共 50 条
  • [21] Emerging pharmacotherapy for obesity
    Aronne, Louis J.
    Powell, Amanda G.
    Apovian, Caroline M.
    EXPERT OPINION ON EMERGING DRUGS, 2011, 16 (03) : 587 - 596
  • [22] Pharmacotherapy for obesity: What you need to know
    Bersoux, Sophie
    Byun, Tina H.
    Chaliki, Swarna S.
    Poole, Kenneth G., Jr.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2017, 84 (12) : 951 - 958
  • [23] Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects
    Montan, Peter D.
    Sourlas, Andreas
    Olivero, Jiohanna
    Silverio, Delia
    Guzman, Eliscer
    Kosmas, Constantine E.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (16)
  • [24] Pharmacotherapy for obesity in individuals with type 2 diabetes
    Chukir, Tariq
    Shukla, Alpana P.
    Saunders, Katherine H.
    Aronne, Louis J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (03) : 223 - 231
  • [25] Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity
    Nigro, Stefanie C.
    Luon, Darren
    Baker, William L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (07) : 839 - 848
  • [26] Current Options for the Pharmacotherapy of Obesity
    Gouni-Berthold, Ioanna
    Berthold, Heiner K.
    CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (18) : 2019 - 2032
  • [27] Pharmacotherapy of obesity: Available medications and drugs under investigation
    Pilitsi, Eleni
    Farr, Olivia M.
    Polyzos, Stergios A.
    Perakakis, Nikolaos
    Nolen-Doerr, Eric
    Papathanasiou, Aimilia-Eirini
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 92 : 170 - 192
  • [28] Treatment of Obesity With "Combination" Pharmacotherapy
    Rothman, Richard B.
    AMERICAN JOURNAL OF THERAPEUTICS, 2010, 17 (06) : 596 - 603
  • [29] Pharmacotherapy in the Management of Pediatric Obesity
    Kelly, Aaron S.
    Fox, Claudia K.
    CURRENT DIABETES REPORTS, 2017, 17 (08)
  • [30] The limits and challenges of antiobesity pharmacotherapy
    Gadde, Kishore M.
    Atkins, Katelyn D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (11) : 1319 - 1328